3D simulation technique: using 3D simulation technique
Study summary
This study will evaluate the safety and efficacy of postmarket bioprosthetic aortic valve in patients with severe aortic regurgitation undergoing transapical transcatheter aortic valve replacement based on 3D simulation technology using a prospective, randomized controlled study.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* All of the following conditions must be met for inclusion:
1. Age ≥ 65 years;
2. Symptomatic severe native aortic regurgitation;
3. Aortic valve anatomy assessed by investigator as suitable for transcatheter aortic valve replacement ;
4. Subjects signed a written informed consent and agreed to cooperate with all follow-up examinations.
Exclusion Criteria:
* Patients meeting any of the following exclusion criteria were not included:
1. Active endocarditis;
2. Acute myocardial infarction or unstable angina pectoris, or severe coronary stenosis requiring coronary revascularization within 3 months;
3. Stroke or TIA (transient ischemic attack) within the past 3 months;
4. Any intracardiac mass, left ventricular or atrial thrombus, vegetation detected by echocardiography;
5. Severe obstructive hypertrophic cardiomyopathy (LVOTG peak ≥ 30 mmHg at rest); Note: Literature Basis: Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy 2023
6. History of bleeding tendency or coagulopathy or refusal of blood transfusion;
7. Active gastric ulcer or active gastrointestinal (GI) bleeding within 3 months;
8. Presence of contraindication to anticoagulation or antiplatelet;
9. Complicated with severe other valve diseases requiring concurrent surgical intervention;
10. Prior aortic valve graft (mechanical or bioprosthetic);
11. Severe left ventricular dysfunction, left ventricular ejection fraction \< 30%;
12. Hepatic encephalopathy or acute active hepatitis;
13. Renal dysfunction (eGFR \< 30ml/min calculated according to Cockcroft-Gault formula) and/or ongoing renal replacement therapy;
14. Patients with severe dementia and other poor compliance, unable to ensure the completion of the investigator;
15. Emergency surgery required for any reason;
16. Known hypersensitivity to contrast agents or nitinol memory alloys or porcine products;
17. Patients who are pregnant or plan to become pregnant, or are taking estrogen or estrogen-like drugs (women suspected of becoming pregnant must have a negative serum or urine test for human chorionic gonadotropin before being included in the study);
18. Other patients considered unsuitable for this clinical study by the investigator;
Primary outcome measure(s)
Coaxial ratio of prosthetic aortic valve — 12 months Definition: A coaxial index of less than 4 degrees or a coaxial angle of less than 10 degrees is considered coaxial if one of them is met, and the ratio of coaxial prosthetic aortic valves in the two groups test group (with 3D simulation technique) or control group (without 3D simulation technique) is calculated, respectively Coaxial rate per group = number of coaxial aortic valve prostheses per group/total number of cases per group 100%
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.